Spyrakis, F.; Department of Life Sciences, University of Modena and Reggio Emilia, Via Campi 103, Modena, 41125, Italy, Department of Drug Science and Technology, University of Turin, Via Pietro Giuria 9, Turin, 10125, Italy
Santucci, M.; Department of Life Sciences, University of Modena and Reggio Emilia, Via Campi 103, Modena, 41125, Italy
Maso, L.; Department of Biology, University of Padua, Viale G. Colombo 3, Padua, 35121, Italy
Cross, S.; Molecular Discovery Limited, Centennial Avenue, Unit 501 Centennial Park, Borehamwood, Hertfordshire, WD6 3FG, United Kingdom
Gianquinto, E.; Department of Drug Science and Technology, University of Turin, Via Pietro Giuria 9, Turin, 10125, Italy
Sannio, F.; Department of Medical Biotechnology, University of Siena, Viale Bracci 16, Siena, 53100, Italy
Verdirosa, F.; Department of Medical Biotechnology, University of Siena, Viale Bracci 16, Siena, 53100, Italy
De Luca, F.; Department of Medical Biotechnology, University of Siena, Viale Bracci 16, Siena, 53100, Italy
Docquier, Jean-Denis ; Université de Liège - ULiège > Département des sciences de la vie > Centre d'ingénierie des protéines
Cendron, L.; Department of Biology, University of Padua, Viale G. Colombo 3, Padua, 35121, Italy
Tondi, D.; Department of Life Sciences, University of Modena and Reggio Emilia, Via Campi 103, Modena, 41125, Italy
Watkins, R. R. & Bonomo, R. A. β-Lactam Antibiotics. In Infectious Diseases (eds Cohen, J. et al.) 1203–1216 (Elsevier, Amsterdam, 2016).
WHO. Antimicrobial Resistance. Global Report on Surveillance (World Health Organization, Geneva, 2014).
Bush, K. Bench-to-bedside review: the role of β-lactamases in antibiotic-resistant Gram-negative infections. Crit. Care 14, 224 (2010).
Bush, K. Carbapenemases: partners in crime. J. Glob. Antimicrob. Resist. 1, 7–16 (2013).
Farina, D. et al. The inhibition of extended spectrum beta-lactamases: hits and leads. Curr. Med. Chem. 21, 1405–1434 (2014).
Frère, J.-M., Sauvage, E. & Kerff, F. From ‘An enzyme able to destroy penicillin’ to carbapenemases: 70 years of beta-lactamase misbehaviour. Curr. Drug Targets 17, 974–982 (2016).
Ambler, R. P. The structure of beta-lactamases. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 289, 321–331 (1980).
Ambler, R. P. et al. A standard numbering scheme for the class A β-lactamases. Biochem. J. 276, 269 (1991).
Bush, K. The ABCD’s of β-lactamase nomenclature. J. Infect. Chemother. 19, 549–559 (2013).
Tondi, D. et al. Decoding the structural basis for carbapenem hydrolysis by class a beta-lactamases: fishing for a pharmacophore. Curr. Drug Targets 17, 983–1005 (2016).
Jacoby, G. A. AmpC β-lactamases. Clin. Microbiol. Rev. 22, 161–182 (2009).
Hamrick, J. C. et al. VNRX-5133 (Taniborbactam), a broad-spectrum inhibitor of serine- and metallo-β-lactamases, restores activity of cefepime in Enterobacterales and Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 64, e01963-e2019 (2019).
Docquier, J.-D. & Mangani, S. Structure-Function Relationships of Class D Carbapenemases. Curr Drug Targets 17, 1061–1071 (2015).
Olsen, I. New promising β-lactamase inhibitors for clinical use. Eur. J. Clin. Microbiol. Infect. Dis. 34, 1303–1308 (2015).
Linciano, P., Cendron, L., Gianquinto, E., Spyrakis, F. & Tondi, D. T. Years with new delhi metallo-β-lactamase-1 (NDM-1): from structural insights to inhibitor design. ACS Infect. Dis. 5, 9–34 (2019).
Mojica, M. F., Bonomo, R. A. & Fast, W. B1-Metallo-beta-lactamases: where do we stand?. Curr. Drugs Targets 17, 1029–1050 (2016).
Rogers, B. A. et al. Treatment options for new delhi metallo-beta-lactamase-harboring enterobacteriaceae. Microb. Drug Resist. 19, 100–103 (2013).
Lomovskaya, O. et al. Vaborbactam: spectrum of beta-lactamase inhibition and impact of resistance mechanisms on activity in enterobacteriaceae. Antimicrob. Agents Chemother. 61, 1417–1443 (2017).
MacVane, S. H., Crandon, J. L., Nichols, W. W. & Nicolau, D. P. In vivo efficacy of humanized exposures of ceftazidime-avibactam in comparison with ceftazidime against contemporary Enterobacteriaceae isolates. Antimicrob. Agents Chemother. 58, 6913–6919 (2014).
Spellberg, B. & Bonomo, R. A. Editorial Commentary Ceftazidime-Avibactam and Carbapenem-Resistant Enterobacteriaceae “We’re Gonna Need a Bigger Boat”. Clin. Infect. Dis. 63, 1619–1621 (2016).
Liu, B. et al. Discovery of taniborbactam (VNRX-5133): a broad-spectrum serine- and metallo-β-lactamase inhibitor for carbapenem-resistant bacterial infections. J. Med. Chem. 63, 2789–2801 (2019).
Lyu, J. et al. Ultra-large library docking for discovering new chemotypes. Nature 566, 224–229 (2019).
Reynolds, C. Impact of computational structure-based methods on drug discovery. Curr. Pharm. Des. 20, 3380–3386 (2014).
Celenza, G. et al. Phenyl boronic acids development led to validated leads active in clinical strains overexpressing KPC-2: a step against bacterial resistance. ChemMedChem 13, 713–724 (2018).
Spyrakis, F. et al. First virtual screening and experimental validation of inhibitors targeting GES-5 carbapenemase. J. Comput. Aided. Mol. Des. 33, 295–305 (2019).
Tondi, D. et al. Targeting class A and C serine β-lactamases with a broad-spectrum boronic acid derivative. J. Med. Chem. 57, 5449–5458 (2014).
Brindisi, M. et al. Targeting clinically-relevant metallo-β-lactamases: from high-throughput docking to broad-spectrum inhibitors. J. Enzyme Inhib. Med. Chem. 31, 98–109 (2016).
Genovese, F. et al. Design, synthesis and biological evaluation of non-covalent AmpC β-lactamases inhibitors. Med. Chem. Res. 26, 975–986 (2017).
Klein, R. et al. In silico identification and experimental validation of hits active against KPC-2 β-lactamase. PLoS ONE 13, 1–22 (2018).
Breton, M. et al. Iminothiol/thiourea tautomeric equilibrium in thiourea lipids impacts DNA compaction by inducing a cationic nucleation for complex assembly. Biophys. Chem. 145, 7–16 (2009).
Hussain, M., Jawaria, R., Shafiq, Z., Abbas, G. & Naseer, M. M. Ferrocene-based thiosemicarbazones: Solvent effect on thiol-thione tautomerism and conformational polymorphism. J. Organomet. Chem. 846, 121–128 (2017).
Antony, J. et al. Binding of D- and L-captopril inhibitors to metallo β-lactamase studied by polarizable molecular mechanics and quantum mechanics. J. Comput. Chem. 23, 1281–1296 (2002).
King, D. T., Worrall, L. J., Gruninger, R. & Strynadka, N. C. J. New delhi metallo β-lactamase: Structural insights into β-lactam recognition and inhibition. J. Am. Chem. Soc. 134, 11362–11365 (2012).
Spyrakis, F. et al. Structure-based virtual screening for the discovery of novel inhibitors of New Delhi metallo-β-lactamase-1. ACS Med. Chem. Lett. 9, 45–50 (2018).
Sevaille, L. et al. 1,2,4-Triazole-3-thione Compounds as Inhibitors of Dizinc Metallo-β-lactamases. ChemMedChem 12, 972–985 (2017).
Docquier, J. D. & Mangani, S. An update on β-lactamase inhibitor discovery and development. Drug Resist. Updates 36, 13–29 (2018).
Sun, Z., Hu, L., Sankaran, B., Prasad, B. V. V. & Palzkill, T. Differential active site requirements for NDM-1 $β$-lactamase hydrolysis of carbapenem versus penicillin and cephalosporin antibiotics. Nat. Commun. 9, 4524 (2018).
Santucci, M. et al. Computational and biological profile of boronic acids for the detection of bacterial serine- and metallo-β-lactamases. Sci. Rep. 7, 17716 (2017).
Milletti, F., Storchi, L., Sfoma, G., Cross, S. & Cruciani, G. Tautomer enumeration and stability prediction for virtual screening on large chemical databases. J. Chem. Inf. Model. 49, 67–68 (2009).
Sun, C., Wu, J. & Pan, Y. Characterization of novel hydrolysis products of carbapenems by electrospray ionization mass spectrometry. Rapid Commun. Mass Spectrom. 23, 3205–3212 (2009).
Leiris, S. et al. SAR studies leading to the identification of a novel series of metallo-β-lactamase inhibitors for the treatment of carbapenem-resistant enterobacteriaceae infections that display efficacy in an animal infection model. ACS Infect. Dis. 5, 131–140 (2019).
Çınaroğlu, S. S. & Timuçin, E. Comparative assessment of seven docking programs on a nonredundant metalloprotein subset of the PDBbind refined. J. Chem. Inf. Model. 59, 3846–3859 (2019).
Irwin, J. J., Raushel, F. M. & Shoichet, B. K. Virtual screening against metalloenzymes for inhibitors and substrates. Biochemistry 44, 12316–12328 (2005).
Borgianni, L. et al. Mutational analysis of VIM-2 reveals an essential determinant for metallo-β-lactamase stability and folding. Antimicrob. Agents Chemother. 54, 3197–3204 (2010).
Linciano, P. et al. 4-amino-1,2,4-triazole-3-thione as promising scaffold for the inhibition of serine and metallo beta-lactamases. Pharmaceuticals 13, 52 (2020).
Faridoon, et al. 3-Mercapto-1,2,4-triazoles and N-acylated thiosemicarbazides as metallo-β-lactamase inhibitors. Bioorganic Med. Chem. Lett. 22, 380–386 (2012).
Feng, L. et al. N-Heterocyclic dicarboxylic acids: broad-spectrum inhibitors of metallo-β-lactamases with co-antibacterial effect against antibiotic-resistant bacteria. Bioorg. Med. Chem. Lett. 22, 5185–5189 (2012).
Galleni, M. et al. Standard numbering scheme for class B β-lactamases. Antimicrob. Agents Chemother. 45, 660–663 (2001).
Mack, A. R. et al. A standard numbering scheme for class C β-lactamases. Antimicrob. Agents Chemother. 64, e01841-e1919 (2019).
Baroni, M., Cruciani, G., Sciabola, S., Perruccio, F. & Mason, J. A common reference framework for analyzing/comparing proteins and ligands. Fingerprints for Ligands and Proteins (FLAP): theory and application. J Chem inf Model 47, 279–294 (2007).
Spyrakis, F. et al. Targeting cystalysin, a virulence factor of Treponema denticola-supported periodontitis. ChemMedChem 9, 1501–1511 (2014).
Cendron, L. et al. X-ray crystallography deciphers the activity of broad-spectrum boronic acid β-lactamase inhibitors. ACS Med. Chem. Lett. 10, 650–655 (2019).
Feng, B. Y. & Shoichet, B. K. A detergent-based assay for the detection of promiscuous inhibitors. Nat. Protoc. 1, 550–553 (2006).
Quotadamo, A. et al. An Improved Synthesis of CENTA, a Chromogenic Substrate for β-Lactamases. Synlett 27, 2447–2450 (2016).
Docquier, J. D. et al. On functional and structural heterogeneity of VIM-type metallo-β-lactamases. J. Antimicrob. Chemother. 51, 257–266 (2003).
Leiros, H. K. S., Edvardsen, K. S. W., Bjerga, G. E. K. & Samuelsen, Ø. Structural and biochemical characterization of VIM-26 shows that Leu224 has implications for the substrate specificity of VIM metallo-β-lactamases. FEBS J. 282, 1031–1042 (2015).
Brem, J. et al. Structural basis of metallo β-lactamase, serine β-lactamase and penicillin-binding protein inhibition by cyclic boronates. Nat. Commun. 7, 12406 (2016).
McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658–674 (2007).
Winn, M. D. et al. Overview of the CCP4 suite and current developments. Acta Crystallogr. D Biol. Crystallogr. 67, 235–242 (2011).
Murshudov, G. N. et al. REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr. Sect. D 67, 355–367 (2011).
Afonine, P. V. et al. Towards automated crystallographic structure refinement with phenix.refine. Acta Crystallogr. Sect. D. 68, 352–367 (2012).
Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. Sect. D. 66, 486–501 (2010).
Moriarty, N. W., Grosse-Kunstleve, R. W. & Adams, P. D. Electronic ligand builder and optimization workbench (eLBOW): a tool for ligand coordinate and restraint generation. Acta Crystallogr. Sect. D 65, 1074–1080 (2009).
Cagnacci, S. et al. Bloodstream infections caused by multidrug-resistant Klebsiella pneumoniae producing the carbapenem-hydrolysing VIM-1 metallo-β-lactamase: first Italian outbreak. J. Antimicrob. Chemother. 61, 296–300 (2008).
Clinical Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; Approved standard—tenth edition. CLSI document M07–A10. Clin. Lab. Stand. Inst. 10.4103/0976-237X.91790 (2015). DOI: 10.4103/0976-237X.91790
